Nov 4 (Reuters) - Mayne Pharma Group Ltd MYX.AX
* Continues to believe these investigations will not have a material impact on its future earnings
* No assurance can be given as to timing or outcome of investigation
* Disclosed that it was one of several generic companies to receive a subpoena from Antitrust Division Of Us Department Of Justice
* Investigation relating to Mayne Pharma is focused on doxycycline hyclate delayed-release tablets and potassium chloride powders
* Antitrust division of US department of justice seeking information relating to marketing, pricing and sales of select generic products Source text for Eikon: ID:nASX4m8YXZ Further company coverage: MYX.AX